Pulse Explorar nav.journalClub Debates Tendências Pesquisadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Início Explorar nav.journalClub Tendências

⌘+K

December 1, 2015Open Access

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer

Key Points

Key points are not available for this paper at this time.

Abstract

We describe the novel CAD-ALK rearrangement as an oncogene and provide the first evidence of its drugability as a new molecular target in CRC.

Perguntar à IA

Like

Bookmark

Share

View Full Paper

Perguntar à IA

Like

Bookmark

Share

View Full Paper

Cite This Study

Amatu et al. (Tue,) studied this question.

synapsesocial.com/papers/69d70aca99397875bbaa82cc https://doi.org/https://doi.org/10.1038/bjc.2015.401

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Rxdx-101, an Oral Pan-Trk, Ros1, and Alk Inhibitor, in Patients with Advanced Solid Tumors with Relevant Molecular Alterations2014 · 9 citations
229LBA Entrectinib (RXDX-101), an oral pan-Trk, ROS1, and ALK inhibitor in patients with advanced solid tumors harboring gene rearrangements2015 · 14 citations
3Pilot Trial of Combined BRAF and EGFR Inhibition in <i>BRAF</i> -Mutant Metastatic Colorectal Cancer Patients2015 · 277 citations
4Anchored multiplex PCR for targeted next-generation sequencing2014 · 919 citations
5The Nucleotide Synthesis Enzyme CAD Inhibits NOD2 Antibacterial Function in Human Intestinal Epithelial Cells2012 · 34 citations

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer | Synapse